HIV persistence: defective virus copies accumulate rapidly after infection
1 October 2016. Related: Cure-related research.
2016
PrEP update: EU approval, extended access for PROUD participants, TAF studies underway
1 October 2016. Related: HIV prevention and transmission.
Conference materials and online publications
1 October 2016. Related: On the web.
September/October 2016: Volume 17 Number 9/10
1 October 2016. Related: PDFs.
July/August 2016: Volume 17 Number 7/8
1 August 2016. Related: Editorial.
21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa
1 August 2016. Related: Conference reports.
AIDS 2016: online access to conference programme
1 August 2016. Related: Conference reports.
ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms
1 August 2016. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
ZERO HIV transmissions in PARTNER study: most widely reported i-Base article
1 August 2016. Related: Conference reports, HIV prevention and transmission.
PrEP studies at AIDS 2016: includes first preclinical data with EFdA
1 August 2016. Related: Conference reports, HIV prevention and transmission.
Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study
1 August 2016. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir at last available: 48 week results from ONCEMRK study
1 August 2016. Related: Conference reports, Antiretrovirals.
Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2
1 August 2016. Related: Conference reports, Antiretrovirals.
Dolutegravir is superior to boosted atazanavir in women in the ARIA study
1 August 2016. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence
1 August 2016. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
Sub-Saharan African countries moving quickly to recommend “Treat All”
1 August 2016. Related: Conference reports, Treatment access, Guidelines.
Efavirenz associated with suicide risk in analysis from START study
1 August 2016. Related: Conference reports, Side effects.
CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study
1 August 2016. Related: Conference reports, Treatment strategies.
Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio
1 August 2016. Related: Conference reports, Treatment strategies.
Publications launched at AIDS 2016
1 August 2016. Related: Conference reports, Other news.
8th International Workshop on HIV paediatrics, 15-16 July 2016, Durban, South Africa.
1 August 2016. Related: Conference reports.
No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial
1 August 2016. Related: Conference reports, Paediatric care, Drug resistance.
TB 2016, 16-17 July 2016, Durban, South Africa
1 August 2016. Related: Conference reports.
Universal treatment of multi-drug resistant TB is possible within current budgets with generic production
1 August 2016. Related: Conference reports, TB coinfection.
Shortened nine-month MDR-TB treatment works well in children and adolescents
1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.
Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB
1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.
2016 Towards an HIV Cure Symposium, 16-17 July 2016, Durban, South Africa
1 August 2016. Related: Conference reports, Cure-related research.
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 8-10 June 2016, Washington DC, USA
1 August 2016. Related: Conference reports.
Modelling data might support use of low dose 400 mg efavirenz in pregnancy
1 August 2016. Related: Conference reports, Pregnancy.
Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery
1 August 2016. Related: Conference reports, Antiretrovirals, Pregnancy.
BHIVA antiretroviral guidelines updated (2016)
1 August 2016. Related: Guidelines.
PROUD study closes leaving participants without access to PrEP
1 August 2016. Related: HIV prevention and transmission.
EMA overcomes its own prejudice to approve PrEP in Europe: four years too late
1 August 2016. Related: HIV prevention and transmission.
NAT legal challenge forces NHS England to reopen process for PrEP: 45-day public consultation now online
1 August 2016. Related: HIV prevention and transmission.
Two large PrEP studies using two-month infusion of antibodies to prevent HIV infection: oral PrEP included for all participants
1 August 2016. Related: HIV prevention and transmission.
July/August 2016: Volume 17 Number 7/8
1 August 2016. Related: PDFs.
Acknowledgments
15 July 2016. Related: Pipeline report.
HTB supplement: 2016 Pipeline Report
14 July 2016. Related: Special reports, Pipeline report.
Dedications
14 July 2016. Related: Pipeline report.
Executive summary – HIV
14 July 2016. Related: Pipeline report.
Executive summary – tuberculosis
14 July 2016. Related: Pipeline report, TB coinfection.
The antiretroviral pipeline 2016
14 July 2016. Related: Pipeline report, Antiretrovirals.
Fit for purpose: antiretroviral treatment optimisation 2016
14 July 2016. Related: Pipeline report, Fit for purpose, Antiretrovirals.
The paediatric antiretroviral pipeline
14 July 2016. Related: Pipeline report, Antiretrovirals, Paediatric care.
Preventive technologies: antiretroviral and vaccine development
14 July 2016. Related: Pipeline report, Antiretrovirals, HIV prevention and transmission, Vaccines and microbicides.
Research toward a cure and immune-based and gene therapies
14 July 2016. Related: Pipeline report, Cure-related research.
The tuberculosis diagnostics pipeline
14 July 2016. Related: Pipeline report, TB coinfection.
The tuberculosis prevention pipeline
14 July 2016. Related: Pipeline report, TB coinfection.
The tuberculosis treatment pipeline: activity, but no answers
14 July 2016. Related: Pipeline report, TB coinfection.
The paediatric tuberculosis treatment pipeline: beyond pharmacokinetics and safety data
14 July 2016. Related: Pipeline report, Paediatric care, TB coinfection.
2016 hepatitis C virus (HCV) update
14 July 2016. Related: Pipeline report, Hepatitis coinfection.
NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos
2 June 2016. Related: Treatment alerts, Treatment access, HIV prevention and transmission.
In Memory: Paul Blanchard, cofounder HIV i-Base
1 June 2016. Related: In memory.
May/June 2016: Volume 17 Number 5/6
1 June 2016. Related: Editorial.
22nd Annual BHIVA Conference, 19-22 April 2016, Manchester
1 June 2016. Related: Conference reports.
New HBV drugs and non-viral liver disease in HIV positive people
1 June 2016. Related: Conference reports, Hepatitis coinfection, Basic science and immunology.
Non-AIDS mortality in England and Wales in HIV positive vs general population
1 June 2016. Related: Conference reports, Ageing and life expectancy, Research studies.
High prevalence of multiple high-risk HPV infections in young HIV positive gay men
1 June 2016. Related: Conference reports, Coinfections and complications, Vaccines and microbicides.
Anal cancer and HPV screening in HIV positive people
1 June 2016. Related: Conference reports, Cancer and HIV, Vaccines and microbicides.
Increasing demand for community treatment information services
1 June 2016. Related: Conference reports.
Non alcohol fatty acid liver disease: an emerging problem
1 June 2016. Related: Conference reports, Coinfections and complications.
HIV positive people on ART have impaired alveolar immunity
1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona
1 June 2016. Related: Conference reports.
High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries
1 June 2016. Related: Conference reports, Treatment access, Hepatitis coinfection, Other news.
Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries
1 June 2016. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.